BCIQ Profiles

Company Profile Report

Safety committee recommends continuation of Atossa's Ph I endoxifen trial

Atossa Genetics Inc. (NASDAQ:ATOS) said an independent safety committee recommended continuation

Read the full 112 word article

How to gain access

Continue reading with a
two-week free trial.